Lymphoma (includes NHL, HL, CNS Lymphoma)
Featured Articles
(AbbVie) Oct 17, 2018 - If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment. The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which showed longer progression-free survival for IMBRUVICA plus...
Read Article
(Reuters) Oct 10, 2018 - An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan. The panel vote comes after the FDA staff reviewers here said Celltrion's biosimilar, CT-P10, is highly similar to...
Read Article
Latest Articles
October 15, 2018
October 12, 2018
October 12, 2018
October 11, 2018
October 09, 2018
October 09, 2018
October 08, 2018
October 05, 2018
View More
News Commentary
Editor Image
09 Apr, 2018 | by Winston Wong, PharmD
CMS has set the reimbursement for their near normal outpatient rate, thus CMS...
View Comment
Editor Image
15 Mar, 2018 | by H. Jack West, MD
This presentation of data from KEYNOTE-189, CheckMate-227, IMpower150, and some...
View Comment
View More
OBR Green
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.
OBR Blog
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) blog entries.